1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Complicated Intra-Abdominal Infections - Pipeline Review, H2 2014

Complicated Intra-Abdominal Infections - Pipeline Review, H2 2014

  • August 2014
  • -
  • Global Markets Direct
  • -
  • 74 pages

Complicated Intra-Abdominal Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Complicated Intra-Abdominal Infections - Pipeline Review, H2 2014’, provides an overview of the Complicated Intra-Abdominal Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Complicated Intra-Abdominal Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Intra-Abdominal Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Complicated Intra-Abdominal Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Complicated Intra-Abdominal Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Complicated Intra-Abdominal Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Complicated Intra-Abdominal Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Complicated Intra-Abdominal Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Complicated Intra-Abdominal Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Complicated Intra-Abdominal Infections - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Complicated Intra-Abdominal Infections Overview 7
Therapeutics Development 8
Pipeline Products for Complicated Intra-Abdominal Infections - Overview 8
Pipeline Products for Complicated Intra-Abdominal Infections - Comparative Analysis 9
Complicated Intra-Abdominal Infections - Therapeutics under Development by Companies 10
Complicated Intra-Abdominal Infections - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Complicated Intra-Abdominal Infections - Products under Development by Companies 15
Complicated Intra-Abdominal Infections - Companies Involved in Therapeutics Development 16
AstraZeneca PLC 16
Merck and Co., Inc. 17
Melinta Therapeutics, Inc 18
Cubist Pharmaceuticals, Inc. 19
MerLion Pharmaceuticals Pte Ltd 20
Nabriva Therapeutics AG 21
Atox Bio Inc. 22
Tetraphase Pharmaceuticals Inc. 23
Complicated Intra-Abdominal Infections - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(ceftolozane + tazobactam) - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
eravacycline - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
(ceftazidime + avibactam) - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
delafloxacin - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
MK-7655 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
AB-103 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Small Molecules to Inhibit 50S RNA for Infections - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
KBP-7072 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
finafloxacin - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Complicated Intra-Abdominal Infections - Recent Pipeline Updates 51
Complicated Intra-Abdominal Infections - Dormant Projects 62
Complicated Intra-Abdominal Infections - Discontinued Products 63
Complicated Intra-Abdominal Infections - Product Development Milestones 64
Featured News and Press Releases 64
Jul 28, 2014: Tetraphase Pharmaceuticals Completes Enrollment of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections 64
Mar 20, 2014: Tetraphase Pharmaceuticals Provides Update on Clinical Progress of Phase 3 Lead Antibiotic Candidate Eravacycline 65
Dec 16, 2013: Cubist Announces Positive Top-Line Results from Phase 3 Trial of Ceftolozane/Tazobactam in Intra-Abdominal Infections 66
Sep 12, 2013: Ceftazidime/avibactam Combination Receives Qualified Infectious Disease Product (QIDP) Designation from FDA 68
Sep 04, 2013: Tetraphase to Present Data at ICAAC Supporting Its Lead Antibiotic Candidate Eravacycline's Effectiveness against Multi-drug Resistant Pathogens 68
Sep 03, 2013: Tetraphase Doses First Patient in Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections 69
Jul 15, 2013: FDA Grants QIDP Designation to Eravacycline, Tetraphase's Lead Antibiotic Product Candidate 70
May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 71
Jan 07, 2013: Cubist Pharma Provides Update On Infectious Disease Drug Candidate, Ceftolozane 71
Dec 06, 2012: Cubist Pharma's Antibiotic Candidate Ceftolozane Obtains QIDP Designation From FDA 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 74
Disclaimer 74

List of Tables

Number of Products under Development for Complicated Intra-Abdominal Infections, H2 2014 8
Number of Products under Development for Complicated Intra-Abdominal Infections - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Complicated Intra-Abdominal Infections - Pipeline by AstraZeneca PLC, H2 2014 16
Complicated Intra-Abdominal Infections - Pipeline by Merck and Co., Inc., H2 2014 17
Complicated Intra-Abdominal Infections - Pipeline by Melinta Therapeutics, Inc, H2 2014 18
Complicated Intra-Abdominal Infections - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 19
Complicated Intra-Abdominal Infections - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2014 20
Complicated Intra-Abdominal Infections - Pipeline by Nabriva Therapeutics AG, H2 2014 21
Complicated Intra-Abdominal Infections - Pipeline by Atox Bio Inc., H2 2014 22
Complicated Intra-Abdominal Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014 23
Assessment by Monotherapy Products, H2 2014 24
Assessment by Combination Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Complicated Intra-Abdominal Infections Therapeutics - Recent Pipeline Updates, H2 2014 51
Complicated Intra-Abdominal Infections - Dormant Projects, H2 2014 62
Complicated Intra-Abdominal Infections - Discontinued Products, H2 2014 63

List of Figures

Number of Products under Development for Complicated Intra-Abdominal Infections, H2 2014 8
Number of Products under Development for Complicated Intra-Abdominal Infections - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Products, H2 2014 12
Comparative Analysis by Early Stage Products, H2 2014 14
Assessment by Monotherapy Products, H2 2014 24
Assessment by Combination Products, H2 2014 25
Number of Products by Top 10 Target, H2 2014 26
Number of Products by Stage and Top 10 Target, H2 2014 27
Number of Products by Top 10 Mechanism of Action, H2 2014 28
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 29
Number of Products by Top 10 Route of Administration, H2 2014 30
Number of Products by Stage and Top 10 Route of Administration, H2 2014 31
Number of Products by Top 10 Molecule Type, H2 2014 32
Number of Products by Stage and Top 10 Molecule Type, H2 2014 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Asia-Pacific Animal Health Market - Forecast to 2021

Asia-Pacific Animal Health Market - Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The APAC animal health market is estimated to grow at a CAGR of 5.7% during the forecast period, to reach USD 20.25 billion by 2021 from USD 15.32 billion in 2016. Growth in this market can primarily be ...

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Silver sulfadiazine is an antibacterial drug used for making personal care products. Silver sulfadiazine is listed as the essential medicines by World Health Organization and is widely used as an antibiotic ...

Anti-infective Agents Market Analysis By Type (Antibacterial, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Antifungal, Azoles, Echinocandins, Polyenes, Antiviral) And Segment Forecasts To 2024

Anti-infective Agents Market Analysis By Type (Antibacterial, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Antifungal, Azoles, Echinocandins, Polyenes, Antiviral) And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The global anti-infective agents market is expected to reach over USD 111.4 billion by 2024 according to a new report by Grand View Research, Inc. The rising prevalence of infectious diseases such as HIV, ...

Global Feed Antibiotics Market

October 2016 $ 4250

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.